View Exam | PowerPak

1. 74-year-old male presents to the ED with chest pain and is found to have an NSTEMI. He has no prior cardiac history but did have a hemorrhagic stroke two years ago. According to the AHA/ACC NSTEMI 2014 guidelines, which of the following antiplatelet agents would not be appropriate for administration prior to diagnostic angiography?

A. Prasugrel B. Ticagrelor C. Clopidogrel 300 mg D. Clopidogrel 600 mg

2. Based on recent clinical trials, which of the following antiplatelet agents would be best to use in the catherization lab if the cardiologist is concerned that the patient might require near-term CABG?

A. Clopidogrel 600 mg B. Prasugrel 60 mg C. Ticagrelor 180 mg D. Cangrelor by IV infusion

3. After successful PCI, the patient will be discharged on ticagrelor, a beta blocker, a statin, and an ACE inhibitor. All of these drugs are new to the patient. Which of the following statements regarding pharmacist-led educational interventions for this patient is correct?

A. The pharmacist should suggest that the patient return to the hospital within 72 hours of discharge for an educational class on coronary artery disease B. To avoid conflict with discharge instructions given by the cardiologist, the pharmacist should not discuss self-care strategies with the patient C. Best outcomes are achieved when the pharmacist is engaged with the patient throughout the hospitalization and discharge process D. The “Teach Back” method of patient education has not been validated for NSTEMI patients

4. Which of the following P2Y12 inhibitors demonstrated a reduction in both cardiovascular and all-cause mortality in ACS?

A. Ticagrelor B. Clopidogrel C. Prasugrel D. None of the above

5. Which of the following statements are correct?

A. Pharmacists should assess an AMI patient's readiness to learn about his/her medications B. Pharmacists should ensure evidence-based medication when prescribing for an AMI patient C. Pharmacists should limit AMI patient support to inpatient hospitalization encounters D. Both A and B E. A, B and C

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Based on recent clinical trials, which of the following antiplatelet agents would be best to use in the catherization lab if the cardiologist is concerned that the patient might require near-term CABG?

3. After successful PCI, the patient will be discharged on ticagrelor, a beta blocker, a statin, and an ACE inhibitor. All of these drugs are new to the patient. Which of the following statements regarding pharmacist-led educational interventions for this patient is correct?

4. Which of the following P2Y12 inhibitors demonstrated a reduction in both cardiovascular and all-cause mortality in ACS?

5. Which of the following statements are correct?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. Based on recent clinical trials, which of the following antiplatelet agents would be best to use in the catherization lab if the cardiologist is concerned that the patient might require near-term CABG?

3. After successful PCI, the patient will be discharged on ticagrelor, a beta blocker, a statin, and an ACE inhibitor. All of these drugs are new to the patient. Which of the following statements regarding pharmacist-led educational interventions for this patient is correct?

4. Which of the following P2Y12 inhibitors demonstrated a reduction in both cardiovascular and all-cause mortality in ACS?

5. Which of the following statements are correct?

« Return to Activity

Customers who Purchased
this Activity also Purchased